Patents by Inventor Martin DEVENPORT

Martin DEVENPORT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210162006
    Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
    Type: Application
    Filed: October 12, 2020
    Publication date: June 3, 2021
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • Publication number: 20210047410
    Abstract: The present invention relates to compositions of anti-CTLA-4 antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for the reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 18, 2021
    Applicants: Oncolmmune, Inc., Children's Research Institute, Children's National Medical Center
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • Publication number: 20210040212
    Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 11, 2021
    Applicants: Oncolmmune, Inc., University of Maryland, Baltimore
    Inventors: Yang Liu, Pan Zheng, Fei Tang, Mingyue Liu, Martin Devenport, Xuexiang Du, Yan Zhang
  • Patent number: 10799558
    Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: October 13, 2020
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • Publication number: 20200283526
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: February 27, 2020
    Publication date: September 10, 2020
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • Publication number: 20200197485
    Abstract: The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, Sjogren's syndrome, or type I diabetes. The CCD24 protein may comprise a mature human CD24 or a variant thereof.
    Type: Application
    Filed: May 21, 2018
    Publication date: June 25, 2020
    Applicants: ONCOIMMUNE, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • Publication number: 20200181235
    Abstract: The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders
    Type: Application
    Filed: May 15, 2018
    Publication date: June 11, 2020
    Applicants: ONCOIMMUNE, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Ning LI
  • Patent number: 10618960
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: April 14, 2020
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • Publication number: 20190263889
    Abstract: This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
    Type: Application
    Filed: September 19, 2017
    Publication date: August 29, 2019
    Applicants: ONCOIMMUNE, INC., CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG
  • Publication number: 20190127468
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: December 14, 2016
    Publication date: May 2, 2019
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • Publication number: 20190038716
    Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
    Type: Application
    Filed: February 2, 2017
    Publication date: February 7, 2019
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT